Could a malaria vaccine ward off another deadly disease?

NCT ID NCT07416461

Recruiting now Prevention Sponsor: International Vaccine Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the R21/Matrix-M malaria vaccine can also reduce the risk of invasive non-typhoidal Salmonella (iNTS), a serious bacterial infection. Researchers will follow 10,000 children under 5 in the Democratic Republic of Congo who come to health centers with fever. By comparing vaccination status between those who test positive or negative for iNTS, they hope to see if the vaccine offers extra protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: R21/Matrix-M malaria vaccine
What this could lead to: If the malaria vaccine also lowers the risk of invasive non-typhoidal Salmonella, it could provide a dual benefit for children in malaria-endemic regions.
What could go wrong: This is an observational study, not a controlled trial, so results may show correlation rather than causation. The vaccine's effect on iNTS is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE NON-TYPHOIDAL SALMONELLA DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

invasive non-typhoidal salmonellosis malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INVASIVE NON-TYPHOIDAL SALMONELLA DISEASE MALARIA MALARIA VACCINE

Contacts and locations

Locations

Institut National de Recherche Biomedicale (INRB)
RECRUITING

Kinshasa, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.